A phase II trial of 24 Chinese patients with higher-risk chronic myelomonocytic leukemia found that the SIRPα-Fc fusion ...
BOSTON, May 27, 2026 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Merin, director of the leukemia program at Cedars-Sinai ...
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic leukemia (CMML), a rare and aggressive form of blood cancer. CMML is ...
"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
Lupus-like manifestations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) represent a distinct inflammatory syndrome driven by clonal hematopoietic cells rather than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results